Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor

Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor

Item

http://www.wikidata.org/entity/Q41838038

Q41838038

about

Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor

Item

http://www.wikidata.org/entity/Q41838038

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Cell cycle perturbation induce ...... citabine with a Chk1 inhibitor

@en

type

Item

label

Cell cycle perturbation induce ...... citabine with a Chk1 inhibitor

@en

prefLabel

Cell cycle perturbation induce ...... citabine with a Chk1 inhibitor

@en

P1476

Cell cycle perturbation induce ...... citabine with a Chk1 inhibitor

@en

P2093

Alan Eastman

http://www.w3.org/2001/XMLSchema#string

Huagang Hou

http://www.w3.org/2001/XMLSchema#string

John Seigne

http://www.w3.org/2001/XMLSchema#string

Lionel D Lewis

http://www.w3.org/2001/XMLSchema#string

Marc S Ernstoff

http://www.w3.org/2001/XMLSchema#string

Nadeem Khan

http://www.w3.org/2001/XMLSchema#string

Ryan Montano

http://www.w3.org/2001/XMLSchema#string

P2860

A simple practice guide for dose conversion between animals and human

Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays

The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.

Fluorimetric DNA assay for cell growth estimation.

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer

ATR prohibits replication catastrophe by preventing global exhaustion of RPA.

Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.

P304

67754-67768

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.18834

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28978069

http://www.w3.org/2001/XMLSchema#string

P921

xenograft

P932

5620209

http://www.w3.org/2001/XMLSchema#string

Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor

about

Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932